Integrin β3 and CD44 levels determine the effects of the OPN-a splicing variant on lung cancer cell growth

Osteopontin (OPN), a phosphorylated glycoprotein, is frequently overexpressed in cancer. Among the three OPN isoforms, OPN-a is the most highly expressed in lung cancer cell lines and lung tumors. Overexpression of OPN-a greatly reduced CL1-5 lung adenocarcinoma cell growth, but had no effect on growth in A549 lung adenocarcinoma cells. Examination of the expression of integrins and CD44, which are possible OPN-a receptors, revealed that differences in integrin beta 3 levels might explain this discrepancy between CL1-5 and A549 cells. When integrin beta 3 was ectopically expressed in A549 cells, OPN-a inhibited their growth, whereas OPN-a increased cell growth following integrin beta 3 knockdown in CL1-5 cells. This OPN-a-induced increase in growth appeared to result from activation of the CD44/NF kappa B pathway. Our results demonstrated that OPN-a inhibits growth of cells with high integrin beta 3 levels and increases growth via activation of the CD44/NF kappa B pathway in cells with low integrin beta 3 levels. Thus, OPN-a, integrin beta 3, and CD44 interact to affect lung cancer cell growth, and this study may aid in the development of cancer treatment strategies involving these molecules.